Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDX-1127 and SBRT in Prostate Cancer
NCT02284971Phase 1Terminated
- Start
- Nov 2014
- Primary completion
- Apr 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of varlilumab in prostate cancer (PCa) (3 arms). Primary endpoints: Number of adverse events and Immunologic (CD8+ T cell and T regulatory cell (Treg) infiltration). Started Nov 2014; status: terminated.
02
Drugs
varlilumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02284971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02284971.